Leukaemic Transformation in Patients with Haematological Disease Receiving Tumour Necrosis Factor Inhibitors

Author： Ferrer-Marín Francisca   >   Vicente Vicente  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.32, Iss.6, 2012-06, pp. : 423-426

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunosuppressants/tumour necrosis factor inhibitors: Legionnaires' disease: 24 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1385, 2012-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor (TNF) inhibitors are an effective option in the management of Crohn's disease

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 9, 2010-09 ,pp. : 15-18

Adis International

Access to resources Recommend Favorite

Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn's Disease: A Practical Approach

By >   Ordás Ingrid   Ricart Elena  

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 109-120

Adis International

Access to resources Recommend Favorite

Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy

By Smith Jeannina A.   Kauffman Carol A.  

Drugs, Vol. 69, Iss. 11, 2009-07 ,pp. : 1403-1415

Adis International

Access to resources Recommend Favorite

The incidence of neoplasia in patients receiving tumour necrosis factor (TNF) antagonists appears to be less than 4%, with solid tumours being most frequent

By  

Reactions Weekly, Vol. 1, Iss. 1160, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite